Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00034924.xml
Nuklearmedizin 2018; 57(04): 168-169
DOI: 10.1055/s-0038-1668503
DOI: 10.1055/s-0038-1668503
Leserbrief/Letter
Reply to: Appearances are often deceptive
Further Information
Publication History
Publication Date:
20 August 2018 (online)
-
References
- 1 Boy C, Poeppel T, Kotzerke J. et al. Somatostatin receptor PET/CT (SSTR-PET/CT). Nuklearmedizin 2018; 57: 4-17.
- 2 Hicks RJ, Kwekkeboom DJ, Krenning E. et al. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasia: Peptide Receptor Radionuclide Therapy with Radiolabeled Somatostatin Analogues. Neuroendocrinology 2017; 105: 295-309.
- 3 Hope TA, Bergsland EK, Bozkurt MF. et al. Appropriate Use Criteria for Somatostatin Receptor PET Imaging in Neuroendocrine Tumors. J Nucl Med 2018; 59: 66-74.
- 4 Poeppel TD, Boy C, Bockisch A. et al. Peptide receptor radionuclide therapy for patients with somatostatin receptor expressing tumours. German Guideline (S1). Nuklearmedizin 2015; 54: 1-11.
- 5 Rinke A, Wiedenmann B, Auernhammer C. et al. Practice guideline neuroendocrine tumors – AWMF-Reg. 021–27. Z Gastroenterol 2018; 56: 583-681.
- 6 Strosberg J, El-Haddad G, Wolin E. et al. Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors. N Engl J Med 2017; 12 (376) 125-135.
- 7 Sundin A, Arnold R, Baudin E. et al. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Radiological, Nuclear Medicine & Hybrid Imaging. Neuroendocrinology 2017; 105: 212-244.